Expert Interview
Discussing the evolving landscape for HIV treatment, with a focus on Merck's single-tablet regimen of Doravirine/Islatravir.
Ticker(s): MRK, GILD, JNJ, GSKInstitution: University of Maryland
Associate Professor of Medicine in the Division of Infectious Diseases at the University of Maryland School of Medicine and attending physician at the University of Maryland Medical Center, specializing in HIV/AIDS and infectious diseases.
Serves as Director of the HIV Clinic and co-director of the Ryan White HIV Program, mentoring infectious disease fellows and leading multidisciplinary care teams for immunocompromised patients.
Leads research on HIV-associated complications, including opportunistic infections and antiviral resistance, with over 100 publications advancing treatment strategies for HIV in vulnerable populations.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Dec 08, 2025
- Call Time
- 10:00 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
